PEDRO DAGO: Open Payments
NPI 1689637639 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,978 in 165 payments from 20 companies in 2025. Trend: 2023 $1,137 · 2024 $2,296 · 2025 $2,978
Food & beverage: $2,978
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $565 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $420 |
| Axsome Therapeutics, Inc. | 11 | $221 |
| Neurocrine BioSciences, Inc. | 8 | $217 |
| Janssen Pharmaceuticals, Inc | 10 | $204 |
| Corium, LLC | 10 | $184 |
| E.R. Squibb & Sons, L.L.C. | 12 | $183 |
| Supernus Pharmaceuticals, Inc. | 9 | $175 |
| Vanda Pharmaceuticals Inc. | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
Products named: VRAYLAR, CAPLYTA, Auvelity, INGREZZA, SPRAVATO, Azstarys, COBENFY, Qelbree.
Industry payments across IL — which companies pay providers there.
